- PROFESSOR Medicine, Hematology and Medical Oncology
American Board of Internal Medicine
MD, Yale School of Medicine
Internship, Internal Medicine
University of Washington Medical Center
Residency, Internal Medicine
University of Washington Medical Center
Fellowship, Medical Oncology
Dana Farber Cancer Institute
- Dr. Talcott is a Professor of Medicine in the Division of Hematology/Oncology and also Director of the Center for Health Care Quality and Outcomes Research at Mount Sinai Beth Israel Hospital. His clinical focus is on genitourinary cancers.
He graduated from Stanford University in Palo Alto, CA, and, as a Rhodes Scholar, from Oxford University. He received his MD from Yale School of Medicine in New Haven, CT. He completed his residency in Internal Medicine at the University of Washington Affiliated Hospitals in Seattle, WA, and was Chief Resident in Medicine at Harborview Medical Center in Seattle. He completed his clinical fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA, and joined the faculty. He moved to Massachusetts General Hospital to be Director of the Center for Outcomes Research at the MGH Cancer Center, where he remained until moving to New York City to his current position.
Rhodes Scholar, 1994
Biostatistics, Cancer, ProstateDr. Talcott is an outcomes and quality of care researcher, interested in optimal treatment strategies, shared decision making and quality of care, with a focus on genitourinary cancers.
Arch Intern Med 1988;148(12):2561-8..;.
Talcott JA, Thurber WA, Kantor AF, Gaensler EA, Danahy JF, Antman KH, et al. Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med 1989;321(18):1220-3.;.
Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10(2):316-22..;.
Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 1997;15(1):223-9..;.
Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997;89(15):1117-23.;.
Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16(1):275-83..;.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-51..;.
Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001;39(10):1118-30..;.
Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166(2):494-9..;.
Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer. Med Care 2003;41(8):923-36..;.
Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21(20):3777-84..;.
Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003;95(22):1702-10..;.
Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003;21(21):3979-86..;.
Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170(5):1772-6..;.
Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-41..;.
Clark JA, Talcott JA. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. J Clin Oncol 2006;24(27):4457-63..;.
Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol 2006;176(4 Pt 1):1558-63; discussion 63-4..;.
Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 2007;109(8):1599-606..;.
Chen RC, Clark JA, Manola J, Talcott JA. Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account? Cancer 2008;112(1):61-8..;.
Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27(24):3916-22..;.
Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010;303(11):1046-53..;.
Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011;29(30):3984-9..;.
Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011;29(30):3977-83..;.
Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D'Amico AV, et al. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU international 2014;114(4):511-6..;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Talcott did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Cancer Center West 325 W. 15th Street Room Suite J
325 W. 15th Street
New York, NY 10011
10 Union Square - PACC Room 4C
10 Union Square
New York, NY 10003